Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIA, randomised, double-blind, double-dummy, placebo and active comparator controlled, 5-way crossover clinical trial to assess the activity, safety, tolerability and pharmacokinetics of single doses of LAS 100977 administered by inhalation to asthma patients.

Next Previous
Trial Profile

A phase IIA, randomised, double-blind, double-dummy, placebo and active comparator controlled, 5-way crossover clinical trial to assess the activity, safety, tolerability and pharmacokinetics of single doses of LAS 100977 administered by inhalation to asthma patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abediterol (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Almirall S.A.

Most Recent Events

  • 02 Jun 2012 Actual end date (19 Feb 2008) added as reported by European Clinical Trials Database.
  • 01 May 2012 Official title amended as reported by European Clinical Trials Database.
  • 01 May 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2007-003415-31).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top